ELV at a glance
Elevance Health (ELV, SEC CIK 1156039) filed its latest 10-K annual report on February 6, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Elevance Health (ELV) reported revenue of $199.1 billion (up 12.5% from FY2024) and net income of $5.7 billion. Diluted EPS was $25.21.
- As of September 30, 2026, 48 institutional investment managers tracked by SignalX reported holding Elevance Health (ELV) shares worth $32.5 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by PERU RAMIRO G on November 19, 2026 of 1,000 shares at $383.86 per share.
- In the last 90 days, ELV insiders reported 1 open-market purchase ($384K) and 14 open-market sales ($5.2M) on Form 4, a net sale of $4.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $199.1B
- +12.5% vs prior year
- Insiders · 90 days
- 1 buy · 14 sells
- Net −$4.8M
- 13F holders
- 48 funds
- $32.5B · −4 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Health benefits and insurance services built significantly through mergers, acquisitions, joint ventures, and strategic alliances
- Emphasis on risks related to integration and liabilities from recent and future business combinations impacting financials and operations
- Strategic risk focus on dependency on dividends from regulated subsidiaries constrained by state insurance laws and minimum capital requirements
- Intangible assets $39.5B representing 32.5% of total assets, with potential impairment risk tied to business combination performance and market changes
- Highlighted concern over maintaining credit ratings which are critical for competitive position and funding flexibility
Risk Factors
- Risk adjustment audits by CMS and HHS OIG awaiting finalization, with potential retroactive payment adjustments impacting financial results
- Concentration in states like California, NY, Texas, exposed to regional economic downturns affecting enrollment and revenues
- Heavy dependence on third-party pharmacy services via CVS Agreement; failure by CVS to deliver could disrupt pharmacy operations
- Competition and provider consolidation risks with provider groups potentially owned by competitors affecting contracting and pricing
- Cybersecurity risks heightened by remote workforce and evolving regulations (e.g., HIPAA, CCPA, GDPR); breaches could cause fines and reputational damage
Management Discussion & Analysis
- Operating gain and margin defined but no actual % figures or changes provided
- Reportable segments: Health Benefits, CarelonRx, Carelon Services, Corporate & Other; no segment financial performance disclosed
- No cash flow, buyback, dividend, or capex information given
- No forward-looking management outlook, guidance, or key risks mentioned in excerpt
AI summary of the ELV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No risk factors section provided, limiting comparison with the 2025 Form 10-K
- Seasonal healthcare demand and competitive conditions may distort interim results versus full-year performance
- Foreign-currency translation exposure from subsidiaries operating outside the United States
- Medical membership concentration: approximately 44.9 million members as of September 30, 2026
Management Discussion & Analysis
- Quarterly operating revenue $50,440, up 0.7% from $50,087 YoY
- Operating margin 2.5% vs 2.6% YoY, benefit expense ratio 90.6% vs 91.3%
- Best segment: CarelonRx revenue $11,599, up 5.5%, operating margin 5.3% vs 5.1%
- Worst segment: Health Benefits operating gain $3,489, down 20.3%, margin 1.0% vs 1.4%
- Operating cash flow $7,512 vs $4,206; investments $2,303, buybacks $1,688, dividends $1,122, debt repayments $900 year-to-date
- Near-term headwinds: elevated Medicaid medical costs, lower membership, expired APTCs, regulatory changes and Medicare Advantage Star Ratings declining to 49% alts
AI summary of the ELV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- 2026 shareholders’ earnings guidance reaffirmed at least $22.00 per diluted share
- Approximately $7.00 per diluted share of net unfavorable items included in reported guidance
Item EX-99.1: Item EX-99.1
- 3Q operating revenue $50.4B, up 0.7%, while GAAP diluted EPS rose 17.9% to $6.27
- Adjusted diluted EPS $6.99, supported by a $1.85-per-share net non-operating benefit
Item 2.02: Results of Operations and Financial Condition
- Elevance Health announced financial results for the quarter ended September 30, 2026
- Full earnings details, including key metrics and management commentary, appear in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Reaffirmed FY2026 shareholders’ earnings guidance of at least $20.10 per diluted share
- Adjusted FY2026 earnings guidance remains at least $27.00 per diluted share, excluding approximately $6.90 of unfavorable items
AI summaries of ELV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ELV
Don't miss the next ELV filing
- Alerts as it files. A push when ELV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ELV, by share count.
- Ask anything. An AI agent that reads every ELV filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| PERU RAMIRO G | Buy | Nov 19, 2026 | 1,000 | $383.86 |
| LAVU RATNAKAR | Sell | Nov 5, 2026 | 1,300 | $440.00 |
| Kaye Mark | Sell | Oct 22, 2026 | 560 | $437.07 |
| Kaye Mark | Sell | Oct 22, 2026 | 1,160 | $439.25 |
| Kaye Mark | Sell | Oct 22, 2026 | 400 | $434.00 |
| Kaye Mark | Sell | Oct 22, 2026 | 1,660 | $436.20 |
| Kaye Mark | Sell | Oct 22, 2026 | 1,720 | $440.44 |
| Kaye Mark | Sell | Oct 22, 2026 | 321 | $435.25 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $177.0B | $199.1B |
| Operating Income | - | $7.9B | $7.2B |
| Net Income | $6.0B | $6.0B | $5.7B |
| Op. Margin | - | 4.4% | 3.6% |
| Net Margin | - | 3.4% | 2.8% |
| Balance Sheet | |||
| Total Assets | $108.9B | $116.9B | $121.5B |
| Equity | - | $41.3B | $43.9B |
| ROE | - | 14.5% | 12.9% |
| Per Share | |||
| EPS | $25.22 | $25.68 | $25.21 |
| Cash Flow | |||
| Operating CF | - | $5.8B | $4.3B |
| CapEx | $1.3B | $1.3B | $1.1B |
Source: XBRL data in Elevance Health (ELV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ELV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 48 | $32.55B |
| Q2 2026 | 52 | $32.48B |
| Q1 2026 | 50 | $24.67B |
| Q4 2025 | 49 | $30.77B |
| Q3 2025 | 53 | $28.03B |
| Q2 2025 | 53 | $33.75B |
| Q1 2025 | 51 | $24.92B |
| Q4 2024 | 45 | $18.37B |
- AQR Capital Management+1.40M (+328%)
- Bank of America Corp+877.2K (+49%)
- Invesco Ltd+834.0K (+20%)
- BlackRock+532.8K (+3%)
- JPMorgan Chase & Co+399.4K (+40%)
- Millennium Management−723.6K (-99%)
- Goldman Sachs Group−593.1K (-30%)
- Citadel Advisors LLC−518.1K (-57%)
- Vanguard Capital Management LLC−234.8K (-2%)
- T. Rowe Price Group−138.8K (-3%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 401 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ELV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 10-Q | Oct 21, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 21, 2026 | - | Analysis | - |
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 10-Q | Jul 15, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - |
Related Health Care companies
- ALHC · Alignment Healthcare, Inc.Hospital & Medical Service Plans
- CNC · Centene CorporationHospital & Medical Service Plans
- CI · CignaHospital & Medical Service Plans
- CLOV · CLOVER HEALTH INVESTMENTS, CORP. /DEHospital & Medical Service Plans
- HUM · HumanaHospital & Medical Service Plans
- MOH · Molina HealthcareHospital & Medical Service Plans
- OSCR · Oscar Health, Inc.Hospital & Medical Service Plans
- TRUP · TRUPANION, INC.Hospital & Medical Service Plans
ELV SEC filings: frequently asked questions
Are ELV insiders buying or selling?
In the last 90 days, Elevance Health (ELV) officers, directors and 10% owners reported 1 open-market purchase worth $383,860 by 1 insider and 14 open-market sales worth $5.2 million by 2 insiders on Form 4, a net sale of $4.8 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ELV stock?
As of September 30, 2026, the largest Elevance Health (ELV) holders among the 13F filers tracked by SignalX were BlackRock ($7.6 billion), Vanguard Capital Management LLC ($5.4 billion), State Street Corp ($4.1 billion), Vanguard Portfolio Management LLC ($2.4 billion), Invesco Ltd ($2.0 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ELV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Elevance Health (ELV) reported revenue of $199.1 billion (up 12.5% from FY2024) and net income of $5.7 billion. Diluted EPS was $25.21. The figures come from the XBRL data in the 10-K.
What are the main risks in ELV's latest 10-K?
In the 10-K filed February 6, 2026, Elevance Health (ELV) flagged: Risk adjustment audits by CMS and HHS OIG awaiting finalization, with potential retroactive payment adjustments impacting financial results. Concentration in states like California, NY, Texas, exposed to regional economic downturns affecting enrollment and revenues. (AI summary of the Risk Factors section.)
What did ELV report in its latest 8-K?
Elevance Health (ELV) filed an 8-K on November 10, 2026 reporting Item 7.01 (Regulation FD Disclosure). 2026 shareholders’ earnings guidance reaffirmed at least $22.00 per diluted share.
What are the latest ELV SEC filings?
Elevance Health (ELV) filed its latest 10-K annual report on February 6, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 20, 2026.
What is ELV's SEC CIK number?
Elevance Health (ELV)'s SEC Central Index Key (CIK) is 1156039. EDGAR lists every ELV filing under that number.
Ask anything about ELV
The research agent reads ELV's filings, financials, insider trades and 13F holders, then answers with sources.